| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Tanox, Inc. |
| 10301 Stella Link, Suite 110, Houston, TX 77025 * (713) 664-2288 |
| Business Description | The company identifies and develops therapeutics monoclonal antibodies to address significant unmet medical needs in areas of immunology, infectious diseases and cancer. |
| Offering Information Company has | |||
| Trading As | TNOX (NASNTL) | Industry | Pharmaceutical (SIC 2836) |
| Type of Stock Offered | Common Shares | Filing Date | 2/2/00 |
| Domestic Shares Offered | 7,500,000 | Offer Date | 4/6/00 |
| Foreign Shares Offered | 0 | Filing Range | $27.00 - $30.00 |
| Company Shares | 7,500,000 | Offer Price | $28.50 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.990 |
| Gross Proceeds | $213,750,000 | Selling | $1.200 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 40,790,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| CIBC World Markets | Lead Manager | (212) 667-7400 |
| Adams, Harkness & Hill | Co-manager | (617) 371-3705 |
| KBC Securities | Co-manager | |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| Warburg Dillon Read LLC | Co-manager | (203) 719-3000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 8.939 | 2.422 | 1.405 | - | - |
| Income from Oper. | - | - | -0.217 | -12.942 | -24.340 | - | - |
| Net Income | - | - | 0.630 | -10.169 | -23.346 | - | - |
| E.P.S | - | - | 0.020 | -0.350 | -0.750 | - | - |
| Revenue Growth (%) | - | - | -72.91 | -41.990 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | 7.05 | - | - | - | - |
| Cash Flow - Oper. | -8.20 | - | - | ||||
| Cash Flow - Inv. | 0.93 | - | - | ||||
| Cash Flow - Fin. | 22.99 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 55.33 | Current Assets | 48.04 | Current Ratio | 9.03 |
| Total Liab. | 15.32 | Current Liab. | 5.32 | Debt Ratio | 27.69% |
| Total Equity | 40.01 | Working Cap. | 42.72 | Debt to Equity Ratio | 0.38 |
| Cash | 44.24 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, for capital expenditures, to finance possible acquisitions and investments in technology, products or businesses and for working capital and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | White, Williams & Martin |
| Bank's Law Firm | Skadden, Arps, Slate, Meagher & Flom |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Nancy T. Chang | 20.80 | |
| Tse Wen Chang | 19.70 | |
| Novartis AG | 19.10 | |
| Alafi Capital Company | 6.90 | |
| Note: represents ownership of 5% or more prior to the offering. | ||